Anne-Christine Bay-Jensen

Head of Rheumatology

Anne-Christine Bay-Jensen

Education:
University of Copenhagen - M.Sc., Biochemistry and Immunology
University of Southern Denmark - Ph.D., Cell biology and Pathology
AVT Business School - mMBA, Business Administration and Management, General

Dr. Anne C. Bay-Jensen has been working with Nordic Bioscience since 2008 and assumed the position as Head of Rheumatology in 2009.

Anne has focused her interest into different aspects of rheumatology with special emphasis on the development of biomarkers for personalized medicine and health care. Anne’s research has centered on three areas; i) In vitro, in vivo and in situ investigation of the chondroprotective effect of candidate drugs for the treatment of inflammatory joint diseases, ii) understanding joint pathology, enabling the development of disease-specific markers, and iii) identification and validation of biomarkers for inflammatory diseases such as osteoarthritis, rheumatoid arthritis and ankylosing spondylitis, and recently also in inflammatory bowel disease and systemic sclerosis. Anne’s research has resulted in the development of the panel of biomarkers that are predictive of progression and treatment response in rheumatoid arthritis and osteoarthritis.

During her scientific career Anne authored or co-authored more than 100 peer-reviewed articles in leading journals and has an H-factor of 31 (JUNE 2017).

Asger Bihlet

Medical Director

Asger Bihlet

Education:
University of Copenhagen - M.Sc., Pharmacy

Asger R. Bihlet joined Nordic Bioscience Clinical Development in 2013.

Asger has wide experience from several areas of the pharmaceutical industry with previous positions including 6 years as Head of Regulatory Affairs and later as Medical Advisor within the fields of cardiovascular diseases and oncology during which he has played an integral part in the design, initiation and wrap-up of several clinical projects. Asger currently leads the Medical Affairs activities in Nordic Bioscience Clinical Development, including heading the pharmacovigilance and regulatory affairs activities.

Asger is actively researching and publishing in the fields of osteoarthritis and chronic obstructive pulmonary disease, with a particular focus on optimizing clinical trial design and outcome.

Diana Julie Leeming

Head of Fibrosis

Diana Julie Leeming

Education:
Aalborg University - M.Sc., Genetechnology, Immunology and Analytical Chemistry
Technical University Denmark - Ph.D, Biochemical Markers
AVT Business School - mMBA, Business Administration and Management, General

Diana Julie Leeming joined Nordic Bioscience in 2004 and assumed the position as Head of Fibrosis in 2009.

Diana is responsible for guiding a team of 15 people working on the Protein Fingerprint Technology including development, characterization and lab production of enzyme-linked immunosorbent assays (ELISAs) for serological biomarker assessments and design of animal studies. Diana has been a part of most research and development processes and is deeply involved in the development and validation of biomarkers, including discovery, project design, establishment of proof-of-concept, patenting, assay characterization, feasibility, product development, and upscaling of production. Diana also works on large as wells as small RnD and Fee-for-Service projects for clients.

Diana has published more than 90 peer-reviewed articles in leading journals during her career and has an H-factor of 31 (June 2017).

Federica Genovese

Head of Kidney Fibrosis

Federica Genovese

Education:
University of Turin - M.Sc., Veterinary Biotechnology
University of Turin - Ph.D., Biochemistry, Microbiology and Biotechnology

Federica Genovese joined Nordic Bioscience in 2011 and assumed the position as Head of Kidney Fibrosis in 2014.

Federica focuses her research in biomarker discovery for extracellular matrix remodeling in fibrosis, with special focus on kidney and cardiovascular diseases.

Federica is deeply involved in our Protein Fingerprint Technology from target identification to lab production of enzyme-linked immunosorbent assays (ELISAs) for urinary- and serological biomarker assessments. Moreover, Federica is responsible for the management of several projects within Nordic Bioscience and European Consortia in the field of lung- and kidney fibrosis and rheumatology. She also works with clients for customized assay development, Fee-for-Service and Pilot Projects.

Federica has published more than 29 peer-reviewed articles in leading journals during her career and has an H-factor of 11 (June 2017).

Kim Henriksen

Head of Musculoskeletal Diseases

Kim Henriksen

Education:
University of Copenhagen - M.Sc., Biochemistry
University of Southern Denmark - PhD, Cell Biology
AVT Business School - mMBA, Business Administration and Management, General

Kim Henriksen joined Nordic Bioscience in 2002 and assumed the position as Head of Muscoloskeletal Diseases 2011.
 
Kim’s research has focused primarily on three areas; i) the development of novel therapeutic peptides for the indications: type 2-diabetes, obesity and NASH, which has research has resulted in several peptide candidates in preclinical development and 1 in clinical testing and ii) the potential of protein fragments as biomarkers of both musculoskeletal diseases and, more recently, neurodegenerative diseases, which has resulted in assays measuring degradation of tau in blood, which are being explored for their prognostic ability within dementias.

During his scientific career Kim has published more than 130 peer-reviewed articles and given numerous oral presentations at international meetings. Kim has an H-factor of 34 (JUNE 2017).

Tina Manon-Jensen

Head of Antibody Research

Tina Manon-Jensen

Tina Manon-Jensen
Education:
ErhvervsAkademi Zealand – scientific laboratory technician
University of Copenhagen - M.Sc., Biology and Technology
University of Copenhagen - Ph.D, Health Science

Tina Manon-Jensen joined Nordic Bioscience in 2013 and assumed the position as Head of Antibody Research in 2014.

Tina is leading the team responsible for development and production of neo-epitope monoclonal antibodies based on Nordic Bioscience’s Protein Fingerprint Technology. Tina is deeply involved in the discovery and design phase of these biomarkers and in addition Tina is principle investigator in the discovery and development of biomarkers within tissue repair and wound healing, a common denominator of several diseases including bleeding disorders, fibrosis and autoimmune diseases.

Tina is an upcoming scientist that has worked with lead scientists within the field of proteoglycans and extracellular matrix both in Denmark as well as in Germany. She has more than 20 publications including high-cited reviews and has an H-factor of 6.